Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Condition(s):Breast Cancer; Ovarian Cancer; Breast Neoplasms; Ovarian Neoplasms; BRCA Mutation; HER2-positive Breast Cancer; HER2-negative Breast Cancer; HER-2 Protein OverexpressionLast Updated:July 12, 2023Enrolling by invitation